Description
What are Betavert 8 Mg Tablets?
Betavert 8 Mg Tablets are oral tablets manufactured by Sun Pharmaceutical Industries Ltd., India’s largest pharmaceutical company. Each tablet contains 8 mg of Betahistine Dihydrochloride as the active ingredient. Betahistine is a histamine analogue that acts on receptors in the inner ear and vestibular system to reduce the frequency and severity of vertigo attacks and associated symptoms such as tinnitus and hearing impairment.
Betavert 8 is indicated primarily for the management of Ménière’s disease — a disorder of the inner ear characterised by recurrent episodes of vertigo, fluctuating hearing loss, tinnitus (ringing in the ears), and a sensation of fullness or pressure in the ear. It is also used for vestibular vertigo arising from other labyrinthine disorders. Each pack contains 10 tablets.
Composition and Product Details
| Brand Name | Betavert 8 |
|---|---|
| Generic Name | Betahistine Dihydrochloride |
| Strength | 8 mg per tablet |
| Dosage Form | Oral tablet |
| Pack Size | 10 tablets (1 strip) |
| Manufacturer | Sun Pharmaceutical Industries Ltd., India |
| Therapeutic Class | Vestibular / Anti-vertigo Agent |
| Prescription Required | Yes |
About Sun Pharmaceutical Industries Ltd. and the Betavert Brand
Sun Pharmaceutical Industries Ltd. is India’s largest pharmaceutical company and one of the top five generic pharmaceutical companies in the world. Established in 1983 and headquartered in Mumbai, Sun Pharma operates in over 100 countries and manufactures a wide range of generic and branded medicines across cardiology, neurology, psychiatry, dermatology, diabetology, and other therapeutic areas.
Sun Pharma is listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) of India, and its products are approved by major regulatory bodies including the US FDA, the UK MHRA, the European EMA, and WHO-GMP authorities. The company is well regarded for its adherence to international quality standards across its global manufacturing network.
The Betavert brand is Sun Pharma’s betahistine product line, available in multiple strengths to support the individualised dosing of betahistine required for long-term Ménière’s disease management. Betavert 8 Mg is the lower-strength tablet in this range, suitable for treatment initiation or for patients whose optimal dose falls within the lower end of the therapeutic range.
How Betavert 8 Mg Works
Betahistine is a structural analogue of histamine that exerts its therapeutic effects through two complementary mechanisms within the inner ear and vestibular system:
- H1 receptor agonism — improved inner ear microcirculation: Betahistine acts as a partial agonist at histamine H1 receptors located on the smooth muscle of the blood vessels supplying the inner ear (cochlea and labyrinth). This causes vasodilation and increases cochlear and labyrinthine blood flow, which helps to reduce the pathological buildup of endolymph (inner ear fluid) that is central to the symptoms of Ménière’s disease. Reduced endolymphatic pressure correlates with fewer and less severe vertigo attacks.
- H3 receptor antagonism — modulation of vestibular neurotransmission: Betahistine also acts as an antagonist at histamine H3 autoreceptors located on histaminergic neurons in the hypothalamus and vestibular nuclei of the brainstem. By blocking H3 receptors, betahistine increases histamine release and enhances histaminergic neurotransmission in the central vestibular pathways. This results in reduced activity in the over-responsive vestibular nuclei that drive the perception of vertigo.
Together, these two mechanisms — peripheral vasodilation in the inner ear and central modulation of vestibular neurotransmission — reduce both the frequency of acute vertigo episodes and the severity of background symptoms including tinnitus and hearing impairment associated with Ménière’s disease.
Betahistine is not a fast-acting rescue medication; it requires consistent daily use over weeks to months to produce its full therapeutic benefit. The medication does not cure Ménière’s disease but helps to control and reduce its symptoms with long-term maintenance therapy.
Indications and Uses
Betavert 8 Mg Tablets are indicated for:
- Ménière’s disease: Long-term treatment of the symptoms of Ménière’s syndrome, including vertigo, tinnitus, hearing loss, and the sensation of pressure or fullness in the affected ear.
- Vestibular vertigo: Management of symptomatic vertigo arising from disorders of the labyrinth (inner ear), including vestibular neuritis and labyrinthitis.
Betahistine is not indicated for the immediate relief of acute vertigo attacks; short-term symptomatic management of acute episodes may require additional medications as directed by a physician. Betavert 8 is a maintenance therapy taken daily to reduce the frequency and severity of episodes over time.
Dosage and Administration
Dosing must be directed by the treating physician based on symptom severity, patient response, and tolerability. Betavert 8 Mg Tablets should be taken with food to reduce the risk of nausea. Tablets are swallowed whole with water and should not be chewed.
- Typical adult dose: 8–16 mg three times daily (total daily dose: 24–48 mg). The 8 mg three times daily regimen (24 mg/day) is the standard starting dose; the physician may titrate upward to 48 mg/day if the response is insufficient.
- Frequency: Three times daily, distributed evenly throughout the day (e.g., with breakfast, lunch, and dinner).
- Duration: Long-term maintenance is typically required. A minimum trial of several weeks (often 3 months) is necessary before assessing therapeutic benefit; response may continue to improve over months of treatment.
Do not stop taking Betavert abruptly without medical advice. Your doctor will advise on dose adjustments or when treatment may be tapered or discontinued based on your individual response.
Special Populations
Elderly (≥65 years)
No specific dose adjustment is considered necessary in elderly patients based on available pharmacokinetic data; however, older patients should be monitored for tolerability, particularly gastrointestinal side effects and any effects on existing conditions such as asthma or peptic ulcer disease. Start at the lower end of the dose range.
Renal Impairment
Limited data are available for patients with severe renal impairment. Betahistine should be used with caution in this population and under close medical supervision. Consult the prescribing physician regarding dose appropriateness.
Hepatic Impairment
As betahistine is metabolised by monoamine oxidase (MAO) enzymes, caution is warranted in severe hepatic impairment where drug metabolism may be altered. Use only under medical supervision in this group.
Paediatric Use
The safety and efficacy of betahistine in children and adolescents have not been established. Betavert 8 Mg is not recommended for use in patients under 18 years of age.
Pregnancy and Breastfeeding
There are insufficient clinical data to assess the safety of betahistine in pregnancy. As a precaution, betahistine should be avoided during pregnancy unless the potential benefit clearly outweighs the risk. It is not known whether betahistine is excreted in human breast milk; breastfeeding is not recommended during treatment. Discuss the risks with your doctor.
Precautions and Warnings
- Phaeochromocytoma: Betahistine is contraindicated in patients with phaeochromocytoma (a tumour of the adrenal gland that secretes adrenaline), as betahistine’s histaminergic activity may provoke a dangerous hypertensive crisis in this condition.
- Bronchial asthma: Betahistine has histamine-like activity and may theoretically exacerbate asthma by promoting bronchoconstriction at higher doses. Use with caution in patients with active asthma, with close monitoring by a physician.
- History of peptic ulcer disease: As with histamine-related drugs, betahistine may stimulate gastric acid secretion and should be used with caution in patients with active or recent peptic ulcer disease. Taking tablets with food reduces gastrointestinal discomfort.
- Antihistamine medications: Concurrent use of antihistamines (H1-receptor antagonists) may reduce the efficacy of betahistine, as both compete for H1 receptor binding. Discuss this interaction with your doctor if you take allergy medications.
- Hypersensitivity: Cases of hypersensitivity reactions, including skin rash and angioedema (swelling of the face, lips, or throat), have been reported. Discontinue and seek medical attention if these occur.
- Driving and machinery: Ménière’s disease itself can impair the ability to drive or operate machinery. Betahistine is not known to cause sedation, but the underlying condition’s episodes of vertigo are a safety concern; discuss driving safety with your doctor.
Contraindications
- Phaeochromocytoma (adrenal medullary tumour) — risk of life-threatening hypertensive crisis
- Hypersensitivity to betahistine dihydrochloride or any excipient in the formulation
- Patients under 18 years of age — insufficient safety and efficacy data
Possible Side Effects
Common (may affect up to 1 in 10 users)
- Nausea
- Abdominal discomfort or dyspepsia
- Headache
Gastrointestinal side effects are the most commonly reported adverse effects of betahistine and are generally mild to moderate. Taking tablets with food significantly reduces nausea and stomach discomfort.
Uncommon
- Vomiting
- Bloating
- Skin rash
- Itching (pruritus)
Rare but Serious
- Hypersensitivity reactions including urticaria (hives) or angioedema — seek immediate medical attention
- Anaphylaxis (very rare) — severe allergic reaction with difficulty breathing, swelling, rapid heart rate; call emergency services immediately
- Bronchospasm (in patients with asthma) — seek medical attention
Report any unexpected or severe side effects to your doctor or pharmacist promptly.
Drug Interactions
- Antihistamines (H1 receptor antagonists) (e.g., cetirizine, loratadine, diphenhydramine, chlorphenamine): Compete with betahistine at H1 receptors and may reduce its therapeutic efficacy. Avoid concurrent use where possible; discuss with your doctor or pharmacist if you need allergy medication.
- MAO inhibitors (MAOIs) (e.g., phenelzine, tranylcypromine, selegiline): Betahistine is metabolised by MAO enzymes. Concurrent use with MAOIs may increase betahistine plasma concentrations through inhibition of its metabolism, potentially enhancing effects and adverse reactions. This combination should generally be avoided.
- Theophylline and other xanthine derivatives: No clinically significant interaction documented, but caution is warranted in asthmatic patients who take both.
- Alcohol: No specific interaction has been documented, but patients with vertigo are advised to limit alcohol as it can worsen balance and vestibular symptoms.
Related Neurological and Vestibular Products on IndoGenMed
IndoGenMed stocks a range of products for the management of neurological and vestibular conditions:
- Betavert 16 Mg Tablets — The 16 mg betahistine tablet in the Betavert range by Sun Pharma, providing a higher per-tablet dose for patients whose physician has established a higher daily betahistine requirement for Ménière’s disease management.
Storage Instructions
- Store below 25°C in a cool, dry place away from direct sunlight and moisture
- Keep tablets in the original blister strip until use
- Store out of reach of children and pets
- Do not use tablets after the printed expiry date
- Do not store in a bathroom or near a sink where humidity is high
Frequently Asked Questions
Q: How long does Betavert 8 take to work?
A: Betahistine is not a fast-acting treatment. Unlike medications that relieve acute vertigo, betahistine works by gradually improving inner ear blood flow and modulating vestibular nerve activity over time. Patients may begin to notice a reduction in the frequency of vertigo episodes within a few weeks, but the full benefit typically develops over 3 to 6 months of consistent daily treatment. The NHS recommends that patients give betahistine a fair trial of at least 3 months before assessing its effectiveness. Continue taking it as prescribed even if you feel well.
Q: Should Betavert 8 be taken with or without food?
A: Betavert 8 Mg Tablets should be taken with food. Taking betahistine with a meal or immediately after eating significantly reduces the risk of nausea and gastric discomfort, which are the most common side effects. Distribute your daily doses evenly across mealtimes — for example, one tablet with breakfast, one with lunch, and one with dinner — to maintain consistent drug levels and minimise stomach upset.
Q: Can I take antihistamines while on Betavert 8?
A: Antihistamines (such as cetirizine, loratadine, or chlorphenamine taken for allergies) work by blocking the same histamine H1 receptors that betahistine acts on. Taking both together can reduce the effectiveness of betahistine. If you need to treat allergy symptoms while on Betavert, speak to your doctor or pharmacist first — they may be able to recommend an approach that does not interfere with your betahistine therapy.
Q: Can Betavert 8 cure Ménière’s disease?
A: No. Betahistine does not cure Ménière’s disease, which is a chronic inner ear condition. Betavert 8 is a long-term management medication that reduces the frequency and severity of vertigo episodes and other symptoms such as tinnitus and hearing impairment. Many patients experience significant reduction in symptoms with sustained treatment. Your specialist will advise on the long-term treatment plan appropriate for your condition, which may include lifestyle modifications, dietary changes (particularly low-sodium diet), and other medical or surgical interventions if required.
Q: Is Betavert 8 safe in patients with asthma?
A: Betahistine has histamine-like activity and could theoretically worsen asthma symptoms or promote bronchoconstriction at higher doses. Betavert 8 Mg can generally be used in patients with well-controlled asthma under close medical supervision, but patients with active or poorly controlled asthma should discuss the risk with their physician before starting treatment. Report any worsening of breathing symptoms immediately.
References
- NHS. Betahistine. NHS.uk. Available at: https://www.nhs.uk/medicines/betahistine/
- MedlinePlus. Betahistine. U.S. National Library of Medicine. Available at: https://medlineplus.gov/druginfo/meds/a601204.html
- European Medicines Agency (EMA). Betahistine — European Public Assessment Report (EPAR). Available at: https://www.ema.europa.eu
- Lacour M, van de Heyning PH, Novotny M, Tighilet B. “Betahistine in the treatment of Ménière’s disease.” Neuropsychiatric Disease and Treatment. 2007;3(4):429–440.
- Committee for Medicinal Products for Human Use (CHMP). Guideline on clinical investigation of medicinal products for the treatment of Ménière’s disease. EMA/CHMP/EWP/75157/2016. Available at: EMA.europa.eu
Reviews
There are no reviews yet.